Search - tctmd.com

Displaying 401 - 420 of 426

Sort: Relevancy | Date

News Daily News

Una Puntuación de Calcio Igual a 0 Ofrece una ‘Ventaja’ sobre la Mortalidad de 15 Años de Duración en Pacientes Asintomáticos

August 06, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

Yael L. Maxwell

June 05, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Daily News

Poor Responders to Statins at Risk for CAD Progression

March 11, 2015

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Presentation TCT 2014

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Presenter: Valentin Fuster, Patrick W. Serruys, Harvey D. White

September 14, 2014

News Conference News TCT 2014

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

September 14, 2014

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

August 28, 2014

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

May 01, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

March 24, 2014

Presentation TCT 2013

PCSK9 Inhibitors: Too Good to Be True?

Presenter: Evan Stein

October 30, 2013

Presentation TCT 2012

PCSK9 Inhibitors: The Holy Grail?

Presenter: Evan Stein

October 23, 2012

Advertisement

Una Puntuación de Calcio Igual a 0 Ofrece una ‘Ventaja’ sobre la Mortalidad de 15 Años de Duración en Pacientes Asintomáticos

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Poor Responders to Statins at Risk for CAD Progression

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Systemic Therapies for the At-Risk Patient: From Darapladib to Anti-inflammatories and PCSK9 Inhibitors

Experts Look to Big Data to Identify New Therapeutic Targets for CVD

Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Phase 3 Pivotal Data on Amgen's Novel Investigational Cholesterol-Lowering Medicine to be Featured at the American College of Cardiology's 63rd Annual Scientific Session

PCSK9 Inhibitors: Too Good to Be True?

PCSK9 Inhibitors: The Holy Grail?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content